123 related articles for article (PubMed ID: 36306194)
1. High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent.
Merola E; Perren A; Rinke A; Zerbi A; McNamara MG; Arsenic R; Fazio N; de Herder W; Valle JW; Gress TM; Wiedenmann B; Pascher A; Pavel ME
J Neuroendocrinol; 2022 Oct; 34(10):e13193. PubMed ID: 36306194
[TBL] [Abstract][Full Text] [Related]
2. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
[TBL] [Abstract][Full Text] [Related]
3. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence.
Merola E; Pascher A; Rinke A; Bartsch DK; Zerbi A; Nappo G; Carnaghi C; Ciola M; McNamara MG; Zandee W; Bertani E; Marcucci S; Modica R; Grützmann R; Fazio N; de Herder W; Valle JW; Gress TM; Fave GD; de Pretis G; Perren A; Wiedenmann B; Pavel ME
Ann Surg Oncol; 2022 Sep; 29(9):5568-5577. PubMed ID: 35583694
[TBL] [Abstract][Full Text] [Related]
4. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
6. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
7. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
[TBL] [Abstract][Full Text] [Related]
9. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.
Merola E; Falconi M; Rinke A; Staettner S; Krendl F; Partelli S; Andreasi V; Gress TM; Pascher A; Arsenic R; Doglioni C; Kaemmerer D; Wiedenmann B; Pavel ME
Am J Surg; 2020 Aug; 220(2):284-289. PubMed ID: 32209239
[TBL] [Abstract][Full Text] [Related]
10. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
11. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U
Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798
[TBL] [Abstract][Full Text] [Related]
12. Distinctive features of pancreatic neuroendocrine neoplasms exhibiting an increment in proliferative activity during the course of the disease.
Alexandraki KI; Kaltsatou M; Kyriakopoulos G; Mavroeidi V; Kostopoulou A; Atlan K; Theocharis S; Rindi G; Grossman AB; Grozinsky-Glasberg S; Kaltsas GA
Endocrine; 2021 Apr; 72(1):279-286. PubMed ID: 33175321
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
14. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
[TBL] [Abstract][Full Text] [Related]
15. Prognostic predictors for recurrence following curative resection in grade I/II pancreatic neuroendocrine tumours.
Chopde A; Gupta A; Chaudhari V; Parghane R; Basu S; Ostwal V; Ramaswamy A; Puranik A; Shrikhande SV; Bhandare MS
Langenbecks Arch Surg; 2023 May; 408(1):204. PubMed ID: 37212896
[TBL] [Abstract][Full Text] [Related]
16. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 cytological index can distinguish well-differentiated from poorly differentiated pancreatic neuroendocrine tumors: a comparative cytohistological study of 53 cases.
Carlinfante G; Baccarini P; Berretti D; Cassetti T; Cavina M; Conigliaro R; De Pellegrin A; Di Tommaso L; Fabbri C; Fornelli A; Frasoldati A; Gardini G; Losi L; Maccio L; Manta R; Pagano N; Sassatelli R; Serra S; Camellini L
Virchows Arch; 2014 Jul; 465(1):49-55. PubMed ID: 24807732
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
19. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties.
Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M
J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808
[TBL] [Abstract][Full Text] [Related]
20. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
